ICVS

ICVS

NLX-101: A Breath of Fresh Air for Patients with Rett Syndrome

Researchers at the Life and Health Sciences Research Institute (ICVS) of the University of Minho have taken an important step in the search for new therapies for Rett Syndrome, a rare neurological disorder that still lacks an effective treatment. The results of the study, now published in the prestigious journal Biomedicine & Pharmacotherapy, show that the experimental drug NLX-101 may alleviate two of the most severe symptoms: irregular breathing and cognitive difficulties.

Malaria Becomes Harder to Treat Due to Multiple Mutations

Malaria is proving more difficult to treat than previously thought, as drug resistance is linked to multiple genetic mutations in the parasite rather than a single one. This is the conclusion of an international study involving scientists from ICVS published in Nature Communications.

ICVS Receives “Excellent” Rating in National FCT Evaluation

The Life and Health Sciences Research Institute (ICVS) has been awarded the highest classification of EXCELLENT in the most recent national evaluation of R&D Units, conducted by the Fundação para a Ciência e a Tecnologia (FCT) under the Multiannual Funding Programme for 2023/2024.

ICVS Researchers Join Innovative GALActIC Study to Combat IAPA

ICVS is a contributing partner in the launch of GALActIC, a pioneering European Union research project aimed at tackling Influenza-associated Pulmonary Aspergillosis (IAPA). The study, led by a European consortium, is funded by the European Partnership for Personalised Medicine (EP PerMed) and promises to pave the way for more effective identification and treatment of this severe condition.